Publications

5674 Results

Monitoring cellular immune responses to cancer immunotherapy

Authors
MA Morse;TM Clay;AC Hobeika;PJ Mosca;HK Lyerly
Journal / Conference
Current Opinion in Molecular Therapeutics 3(1):45-52
Year
2001

Editorial: Surrogate markers of effective anti-tumor immunity

Authors
HK Lyerly;MA Morse;T Clay
Journal / Conference
Annals of Surgical Oncology 8(3):190-191
Year
2001

Gamma interferon expression in CD8+ T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65

Authors
SA Ghanekar;LE Nomura;MA Suni;LJ PIcker;HT Maecker;VC Maino
Journal / Conference
Clinical and Diagnostic Laboratory Immunology 8(3):628-631
Year
2001

Assays for monitoring cellular immune responses to active immunotherapy of cancer

Authors
TM Clay;AC Hobeika;HK Lyerly;MA Morse
Journal / Conference
Clinical Cancer Research 7:1127-1135
Year
2001

Use of overlapping peptide mixtures as antigens for cytokine flow cytometry

Authors
HT Maecker;HS Dunn;MA Suni;E Khatamzas;CJ Pitcher;T Bunde;N Persaud;W Trigona;TM Fu;E Sinclair;BM Bredt;JM McCune;VC Maino;F Kern;LJ Picker
Journal / Conference
Journal of Immunological Methods 255:27-40
Year
2001

Quantitating therapeutially relevant T-Cell responses to cancer vaccines

Authors
AC Hobeika;TM Clay;PJ Mosca;HK Lyerly;MA Morse
Journal / Conference
Critical Review in Immunology 21:287-297
Year
2001

Surrogate markers of response to cancer immunotherapy

Authors
MA Morse;TM Clay;AC Hobeika;PJ Mosca;HK Lyerly
Journal / Conference
Expert Opinion on Biological Therapy 1(2):153-158
Year
2001

Is time to tumor progression (TTP) an appropriate endpoint for clinical trials in anaplastic astrocytomas (AA)? Analysis of Radiation Therapy Oncology Group (RTOG) study 9404

Authors
CB Scott;W Seiferheld;M Prados;M Mehta;HM Sandler;WJ Curran
Journal / Conference
Proc of the American Society of Clinical Oncology 20:51a(#200)
Year
2001
Research Committee(s)
Brain
Study Number(s)
SWOG-9340 (RTOG-9404)

Secondary analysis of RTOG 9310: an Intergroup phase II combined modality treatmetn of primary central nervous system lymphoma with chemotherapy and hyperfractionated radiotherapy

Authors
BJ Fisher;W Seiferheld;C Schultz;L DeAngelis;D Nelson;SC Schold;W Curran
Journal / Conference
Neuro-Oncology 3(4):348-349 (#325)
Year
2001
Research Committee(s)
Brain
Study Number(s)
SWOG-9310 (INT-0143) (RTOG-93-10)

Impact of TNM stage on survival and disease control in adjuvant rectal cancer pooled analysis

Authors
LL Gunderson;DJ Sargent;J Tepper;M J O'Connell;C Allmer;SR Smalley;JA Martenson;DG Haller;R Mayer;TA Rich
Journal / Conference
Int J Radiat Oncol Biol Phys 51(3):8-9(#10)
Year
2001
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-9040